Workflow
ZHEJIANG HISUN BIOMATERIALS CO.LTD.(688203)
icon
Search documents
海正生材: 浙江海正生物材料股份有限公司2024年年度权益分派实施公告
Zheng Quan Zhi Xing· 2025-05-28 10:17
证券代码:688203 证券简称:海正生材 公告编号:2025-30 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 是否涉及差异化分红送转:是 ? 每股分配比例 每股现金红利0.06005元 ? 相关日期 股权登记日 除权(息)日 现金红利发放日 公司于 2025 年 5 月 8 日召开了 2024 年年度股东会,会议审议通过了《2024 年度利润分配预案》,具体分配方案如下: 公司 2024 年度拟以实施权益分派股权登记日登记的总股本扣除公司回购专用 证券账户股份数后的股本为基数分配利润,拟向全体股东每 10 股派发现金 0.60 元(含税)。截至公司 2024 年度利润分配方案披露日,公司总股本 202,678,068 股扣除公司回购专用证券账户股份 1,256,874 股后的股本基数为 201,421,194 股, 以此计算合计拟派发现金红利 12,085,271.64 元(含税)。本年度以现金为对价, 采用集中竞价方式已实施的股份回购金额 8,998,849.64 元(不含印花税、交易佣 金等交 ...
海正生材(688203) - 中信建投证券股份有限公司关于浙江海正生物材料股份有限公司差异化分红事项的核查意见
2025-05-28 10:02
中信建投证券股份有限公司 关于浙江海正生物材料股份有限公司 差异化分红事项的核查意见 自公司2024年年度利润分配方案披露之日至本核查意见出具日,公司通过上 海证券交易所交易系统以集中竞价交易方式实施回购,公司回购专用证券账户中 的股份数由1,256,874股增至1,422,364股,因此,扣减公司回购专用证券账户的股 份数量后,公司本次实际参与权益分派的股份数量为201,255,704股。公司按照现 金分配总额不变的原则,相应调整每股分配比例,每股派发现金红利由0.06元(含 税)调整至0.06005元(含税)。 中信建投证券股份有限公司(以下简称"保荐机构"、"中信建投证券")作为 浙江海正生物材料股份有限公司(以下简称"公司"或"海正生材")首次公开发行 股票并在科创板上市及进行持续督导的保荐机构,根据《上海证券交易所科创板 股票上市规则》《证券发行上市保荐业务管理办法》《上海证券交易所上市公司 自律监管指引第7号——回购股份》等有关法律法规和规范性文件的要求,对海 正生材2024年度利润分配涉及的差异化分红事项进行了核查,并发表核查意见如 下: 一、本次实施差异化权益分派的原因 2024年8月28日, ...
海正生材(688203) - 浙江海正生物材料股份有限公司2024年年度权益分派实施公告
2025-05-28 10:00
| 股权登记日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/5 | 2025/6/6 | 2025/6/6 | 证券代码:688203 证券简称:海正生材 公告编号:2025-30 浙江海正生物材料股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 每股现金红利0.06005元 相关日期 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 8 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后,在中国证券登记结算有限责任 公司上海分公司(以下简称"中国结算上海分公司")登记在册的本公司全体股东 (浙江海正生物材料股份有限公司回购专用证券账户除外)。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 是否涉及差异化分红送转:是 每股分配比例 1. 发放年度:2024年年度 2. 分派对象: 上市公司自律监管指引第 7 号——回 ...
5月15日早间重要公告一览
Xi Niu Cai Jing· 2025-05-15 05:09
Group 1 - Huate Gas plans to reduce its shareholding by up to 2% through block trading from June 9, 2025, to September 8, 2025, totaling no more than 2.4 million shares [1] - Huazhong Co. reported April sales of 208,200 pigs, with a revenue of 375 million yuan, showing a month-on-month decrease of 4.28% [2] - Haizheng Biomaterials intends to reduce its shareholding by up to 1% starting from June 9, 2025, due to funding needs [3] Group 2 - Lisheng Sports plans to repurchase shares worth between 20 million and 40 million yuan for employee stock ownership plans [5] - Hongjing Technology signed a service contract worth 563 million yuan for a smart computing project, lasting five years [6] - Ugreen Technology aims to participate in the pre-restructuring of Zhongzhi Real Estate, targeting 100% equity acquisition [8] Group 3 - Jingquan Hua plans to reduce its shareholding by up to 1.67% starting from June 6, 2025 [9] - New Times plans to reduce its shareholding by up to 0.3% starting from June 6, 2025 [10] - Baofeng Energy intends to repurchase shares worth between 1 billion and 2 billion yuan, with a maximum price of 22.80 yuan per share [10] Group 4 - Yuanli Co. plans to reduce its shareholding by up to 3% starting from June 6, 2025 [14] - Huakai Yibai intends to reduce its shareholding by up to 3% starting from June 6, 2025 [15] - Guangshengtang's innovative hepatitis B drug GST-HG131 has completed Phase II clinical trials, showing significant efficacy [17] Group 5 - Electric Media plans to invest 115 million yuan in a cultural technology venture capital fund, which has a total expected scale of 2 billion yuan [21] - China Merchants Port reported a total of 17.059 million TEUs in April, a year-on-year increase of 6% [23] - Changguang Huaxin plans to reduce its shareholding by up to 2% starting from June 9, 2025 [25] Group 6 - Huace Film plans to reduce its shareholding by up to 1.11% starting from June 6, 2025, to reduce debt [26] - BeiGene's HHLR Fund reduced its shareholding from 6.03% to 4.89% after selling 16 million shares [27] - Heertai plans to reduce its shareholding by up to 2.05% starting from June 6, 2025 [28] Group 7 - Biyin Lefen's director plans to reduce his shareholding by up to 491,300 shares starting from June 6, 2025, due to personal funding needs [29]
破发股海正生材股东拟减持 2022年上市中信建投保荐
Zhong Guo Jing Ji Wang· 2025-05-15 03:41
上市首日,海正生材盘中最高报23.78元,为上市以来最高价。目前该股处于破发状态。 海正生材首次公开发行募集资金总额84,516.75万元,扣除发行费用后,募集资金净额为75,086.12万元。 海正生材最终募集资金净额比原计划少57,501.88万元。海正生材于2022年8月11日披露的招股书显示, 公司拟募集资金132,588.00万元,分别用于年产15万吨聚乳酸项目、研发中心建设项目。 根据公告,持股5%以上股东中国石化集团资本有限公司(以下简称"中石化资本")因经营发展资金需 求,计划自公告披露之日起十五个交易日后的三个月内,通过集中竞价交易方式减持不超过2,026,780 股,占公司总股本比例不超过1%。上述股份减持价格按减持实施时的市场价格确定。 截至公告披露日,中石化资本持有海正生材15,686,274股,占公司总股本的7.74%。上述股份为公司首 次公开发行前取得的股份,并已于2024年2月19日起上市流通。中石化资本为海正生材第二大股东。 本次股份减持计划不会对公司治理结构及持续经营产生重大影响。本次减持计划实施不会导致上市公司 控制权发生变更。 海正生材于2022年8月16日在上交所科创板 ...
5月15日上市公司重要公告集锦:中国石化控股股东首次增持公司3.02亿股H股股份
Zheng Quan Ri Bao· 2025-05-14 13:01
Important Announcements - Sinopec's controlling shareholder has increased its stake by 302 million H-shares, accounting for 0.25% of the total issued shares, with an investment of HKD 1.232 billion [4] - Shenghe Resources plans to acquire Peak Rare Earths Limited for AUD 158 million (approximately RMB 74.26 million), focusing on the Ngualla rare earth project in Tanzania [5] - Qibin Group has terminated the acquisition of 28.78% equity in its subsidiary Qibin Solar Energy due to changes in market conditions and transaction cycles [8] - Baofeng Energy intends to repurchase shares worth between RMB 1 billion and 2 billion, with a repurchase price not exceeding RMB 22.8 per share [9] - Hongjing Technology has signed a service contract for a smart computing project worth RMB 563 million [13] Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% of the company's shares, totaling no more than 2.4 million shares [6] - Haizheng Materials' shareholder, Sinopec Group Capital, intends to reduce its stake by up to 1% of the total shares, approximately 202,680 shares [2] - New Times plans for its directors and deputy general manager to collectively reduce their holdings by up to 0.3% of the company's shares [10] - Jingquan Hua's actual controller and board members plan to reduce their holdings by up to 1.67% of the company's shares [11] Project Developments - China National Petroleum Engineering's subsidiary has won a contract for an overseas project worth RMB 11.538 billion, involving the construction of a gas processing facility in Iraq [3] - Hainan Haicong New Materials is set to establish a new company with a registered capital of RMB 25 million to develop an aluminum alloy door and window project with an investment of RMB 55 million [17] - Huakang Clean has signed a construction contract worth RMB 143 million for a hospital project [18]
海正生材(688203) - 浙江海正生物材料股份有限公司股东减持股份计划公告
2025-05-14 11:34
证券代码:688203 证券简称:海正生材 公告编号:2025-29 浙江海正生物材料股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示: 大股东持股的基本情况 截至本公告披露日,浙江海正生物材料股份有限公司(以下简称"公 司"或"海正生材")持股 5%以上股东中国石化集团资本有限公司(以下 简称"中石化资本")持有公司股份 15,686,274 股,占公司总股本的 7.74%。 上述股份为公司首次公开发行前取得的股份,并已于 2024 年 2 月 19 日起 上市流通。 减持计划的主要内容 因经营发展资金需求,中石化资本计划拟自本公告披露之日起十五个 交易日后的三个月内,通过集中竞价交易方式减持不超过 2,026,780 股, 占公司总股本比例不超过 1%。上述股份减持价格按减持实施时的市场价格 确定。在减持计划实施期间,公司若发生送股、资本公积金转增股本、增 发新股或配股等变动事项,减持股份数量将根据公司届时最新的总股本数 量及减持计划比例进行相应调整。 | 股 ...
海正生材(688203) - 浙江海正生物材料股份有限公司关于调整2024年度利润分配方案每股分配比例的公告
2025-05-14 11:30
证券代码:688203 证券简称:海正生材 公告编号:2025-28 ● 调整原因:自 2024 年年度利润分配方案披露之日起至本公告披露日,浙 江海正生物材料股份有限公司(以下简称"公司")通过上海证券交易所交易系 统以集中竞价方式实施股份回购,故本次实际参与利润分配的股份数量发生变 动。公司按照分配总额不变的原则,相应调整每股分配比例,对 2024 年度利润 分配方案每股现金分红金额进行相应调整。 一、调整前利润分配方案 公司于 2025 年 4 月 11 日召开了第七届董事会第十四次会议、第七届监事会 第十一次会议,并于 2025 年 5 月 8 日召开了 2024 年年度股东大会,会议审议通 过了《2024 年度利润分配预案》。本次利润分配方案如下: 公司 2024 年度拟以实施权益分派股权登记日登记的总股本扣除公司回购专 用证券账户股份数后的股本为基数分配利润,拟向全体股东每 10 股派发现金 0.60 元(含税)。截至公司 2024 年度利润分配方案披露日,公司总股本 202,678,068 股扣除公司回购专用证券账户股份 1,256,874 股后的股本基数为 201,421,194 股,以此计算 ...
海正生材:中石化资本拟减持不超过1%公司股份
news flash· 2025-05-14 11:07
海正生材公告,持股5%以上股东中国石化集团资本有限公司计划减持不超过202.68万股,占公司总股 本比例不超过1%。 ...
海正生材:产销量稳步增长,行业竞争加剧导致盈利承压-20250512
Orient Securities· 2025-05-12 08:23
Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 10.75 CNY based on a 2025 comparable company average P/E ratio of 43 times [2][3]. Core Views - The domestic polylactic acid (PLA) industry is facing intensified competition, leading to downward pressure on product prices and consequently affecting profit margins. The company has adjusted its profit forecasts for 2025-2027, with expected earnings per share of 0.25, 0.32, and 0.42 CNY respectively [2][9]. - Despite achieving record sales volumes, the company's profitability is under pressure due to price declines in PLA products. The company is focusing on increasing production efficiency and exploring new applications, particularly in the rapidly growing 3D printing sector, where PLA resin sales are expected to increase significantly [9][10]. Financial Performance Summary - The company reported a revenue of 753 million CNY in 2023, with a projected increase to 1,030 million CNY in 2025, reflecting a compound annual growth rate (CAGR) of 21.8% [7]. - The net profit attributable to the parent company is expected to decline from 44 million CNY in 2023 to 36 million CNY in 2024, before recovering to 52 million CNY in 2025, indicating a volatile profit trajectory [7][9]. - The gross margin is projected to stabilize around 13.0% in 2025, with net profit margins improving gradually to 5.0% by 2025 [7][9]. Market Dynamics - The report highlights that the PLA import pressure may ease due to recent tariff changes affecting imports from the U.S., which could reduce the overall import volume of PLA into China [9]. - The company is expected to continue developing new products and applications to enhance competitiveness, particularly in the 3D printing market, which has shown robust demand growth [9].